May 8, 2017 Large Cap Biopharma Valuations After Q1 Earnings
Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics:
- Best stock performance YTD are REGN up 15.3%, AMGN up 11.5% and ABBV up 5.73%. The large cap focused IBB was up 9.07% .
- Valuations that appear most attractive based on P/S are: ABBV, GILD. Both have attractive dividends.
- Best growth prospects based on Q/Q are : ALXN, CELG, and REGN. All have a high Price/Sales ratio.
- Best earnings prospects based on PEG and Q/Q are: ABBV,BMY and CELG.
- Rayno Life Science Picks have been: ABBV, AMGN, BIIB, BMY, GILD and RHHBY(data not available).
| Company | Ticker | Price | 2017 | Market | P/S | PEG | Q/Q | Q/Q | Perform | Price 5/8 | % Perf | DIV | |
| 1/7/2016 | Rev$B | Cap $B | REV | EPS | %12 mos | 2017 | YTD | ||||||
| 5/8/2017 | Gr% | Gr% | 5/8/17 | ||||||||||
| Abbvie | ABBV | 57.21 | 26.22 | 104.7 | 4 | 1.21 | 9.7 | 28.1 | 5.92 | 66.21 | 5.73 | 3.87 | |
| Alexion | ALXN | 174.37 | 3.25 | 28 | 8.61 | 3.17 | 24.1 | 85.2 | -11.71 | 124.48 | 1.74 | ||
| Amgen | AMGN | 158 | 22.93 | 120.15 | 5.24 | 2.83 | -1.1 | 11.8 | 6.42 | 163.03 | 11.5 | 2.82 | |
| Biogen | BIIB | 284.01 | 11.53 | 55.81 | 4.84 | 2.02 | 3.1 | -21.8 | -1.21 | 260.42 | -8.17 | ||
| Bristol MyersSqibb | BMY | 65.27 | 19.97 | 91.31 | 4.57 | 2.08 | 12.3 | 32.4 | -22.89 | 54.94 | -6.02 | 2.84 | |
| Celgene | CELG | 111.89 | 11.68 | 92.2 | 7.9 | 2.15 | 17.9 | 17 | 18.1 | 118.36 | 2.25 | ||
| Gilead Sci | GILD | 96.25 | 29.1 | 87.9 | 3.02 | – | -16.5 | -18.8 | -20.6 | 67.21 | -6.14 | 3.09 | |
| Regeneron | REGN | 501.96 | 4.86 | 42.17 | 8.68 | 2.97 | 9.8 | 36.2 | 14.44 | 423.38 | 15.33 | ||
| IBB | 304 | 8.18 | 13.39 | 289.45 | 9.07 | ||||||||
| XBI | 61.82 | 2.75 | 35.52 | 68.25 | 15.31 | ||||||||
| FBIOX | 8.88 | 13.84 | 195.65 | 15 | |||||||||
| FBT | 21.14 | 104.97 | 15.5 | ||||||||||